CN108939128A - With medicament slow release and from the function and service dressing and preparation method thereof of antibacterial effect - Google Patents
With medicament slow release and from the function and service dressing and preparation method thereof of antibacterial effect Download PDFInfo
- Publication number
- CN108939128A CN108939128A CN201810583152.7A CN201810583152A CN108939128A CN 108939128 A CN108939128 A CN 108939128A CN 201810583152 A CN201810583152 A CN 201810583152A CN 108939128 A CN108939128 A CN 108939128A
- Authority
- CN
- China
- Prior art keywords
- wound
- weight
- parts
- dressing
- function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000006260 foam Substances 0.000 claims abstract description 37
- 239000006096 absorbing agent Substances 0.000 claims abstract description 24
- 206010000269 abscess Diseases 0.000 claims abstract description 13
- 239000004626 polylactic acid Substances 0.000 claims abstract description 13
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract description 12
- 229920002635 polyurethane Polymers 0.000 claims abstract description 12
- 239000004814 polyurethane Substances 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 11
- 239000004433 Thermoplastic polyurethane Substances 0.000 claims abstract description 9
- 230000000149 penetrating effect Effects 0.000 claims abstract description 9
- 229920002803 thermoplastic polyurethane Polymers 0.000 claims abstract description 9
- 239000002131 composite material Substances 0.000 claims abstract description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 229920001730 Moisture cure polyurethane Polymers 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 229920001451 polypropylene glycol Polymers 0.000 claims description 10
- 239000004970 Chain extender Substances 0.000 claims description 9
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 9
- 239000003054 catalyst Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 9
- 125000005442 diisocyanate group Chemical group 0.000 claims description 9
- 229920000570 polyether Polymers 0.000 claims description 9
- 229920005862 polyol Polymers 0.000 claims description 9
- 150000003077 polyols Chemical class 0.000 claims description 9
- 229920001661 Chitosan Polymers 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 7
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 6
- 230000018044 dehydration Effects 0.000 claims description 6
- 238000006297 dehydration reaction Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000012948 isocyanate Substances 0.000 claims description 6
- 238000000465 moulding Methods 0.000 claims description 6
- 238000011426 transformation method Methods 0.000 claims description 6
- 208000005156 Dehydration Diseases 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 230000003444 anaesthetic effect Effects 0.000 claims description 4
- 230000000202 analgesic effect Effects 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 4
- 239000002221 antipyretic Substances 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 claims description 3
- 230000001754 anti-pyretic effect Effects 0.000 claims description 3
- 238000005266 casting Methods 0.000 claims description 3
- 239000000701 coagulant Substances 0.000 claims description 3
- 239000012456 homogeneous solution Substances 0.000 claims description 3
- 229940054190 hydroxypropyl chitosan Drugs 0.000 claims description 3
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 125000003944 tolyl group Chemical group 0.000 claims description 3
- 239000004593 Epoxy Substances 0.000 claims description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 claims 1
- 150000004767 nitrides Chemical class 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 51
- 206010052428 Wound Diseases 0.000 abstract description 50
- 241000894006 Bacteria Species 0.000 abstract description 10
- 230000029663 wound healing Effects 0.000 abstract description 5
- 231100000241 scar Toxicity 0.000 abstract description 4
- 208000028990 Skin injury Diseases 0.000 abstract description 3
- 238000005469 granulation Methods 0.000 abstract description 3
- 230000003179 granulation Effects 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 230000010478 bone regeneration Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 229920005830 Polyurethane Foam Polymers 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011496 polyurethane foam Substances 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 3
- 238000007711 solidification Methods 0.000 description 3
- 230000008023 solidification Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000008470 skin growth Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A61F13/01029—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive plasters or dressings
- A61F13/0203—Adhesive plasters or dressings having a fluid handling member
- A61F13/0206—Adhesive plasters or dressings having a fluid handling member the fluid handling member being absorbent fibrous layer, e.g. woven or nonwoven absorbent pad, island dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Abstract
With medicament slow release and from the function and service dressing and preparation method thereof of antibacterial effect, belong to the field of medical instrument technology.Solve existing polyurethanes foam dressing easily to breed bacterium, cannot be used for a long time, and easily with granulation adhesion the technical issues of.Function and service dressing of the invention, by successively compact arranged wound-contacting layer, foam absorber layer and exterior cover sheets form from the inside to the outside；Wherein, wound-contacting layer is the composite material of slow releasing pharmaceutical and degradable poly lactic acid, and penetrating micropore is contained on the surface of wound-contacting layer；Foam absorber layer is aqueous polyurethane foamed material, and foam absorber layer has open abscess unit；Exterior cover sheets are the thermoplastic polyurethane of surface compact.The dressing has excellent antibacterial effect, it is not easy and surface of a wound adhesion, dressing frequency is low, and the Wound healing and bone regeneration of skin injury caused by the reasons such as increase patient comfort while reduces the scar degree of skin, is particularly suitable for device wound, burn, bacterium infection are festered.
Description
Technical field
The present invention relates to a kind of with medicament slow release and from the function and service dressing and preparation method thereof of antibacterial effect, belongs to
The field of medical instrument technology is particularly suitable for device wound, the wound of skin injury caused by the reasons such as burn, bacterium infection are festered
Mouth treatment.
Background technique
Medically for the treatment of skin trauma, one layer of medical dressing usually is coated in wound surface, prevents bacterium, ash
The sundries infected wound such as dirt protects wound healing.Requirement with sufferer to experience property comfortable in wound healing process, dressing
Type is also able to improvement of constantly bringing forth new ideas, and gradually develops to polyurethane foam moist dressing now by traditional hospital gauze class.
Polyurethane foam dressing has excellent hydrophilic absorbent, good gas permeability and higher machinery by force because of it
Degree can provide the environment of high humidity lubricant nature to the surface of a wound, may advantageously facilitate wound healing, gradually become the high-end of medical dressing field
Kind.But high wet environment is equally beneficial for the bacteria breed breeding of surface of a wound itself, polyurethane itself cannot inhibit or kill
Into the bacterium in dressing, therefore dressing need to be regularly replaced.In addition, traditional polyurethane foam dressing, connects with wound
The size of the abscess of contact layer is different, and granulation, which is grown in repair process, to be entered in macrocellular foam, so as to cause the surface of a wound and applies
Expect adhesion, brings tearing pain to patient when not only dressing is uncovered, but also easily leave different incrustation scar to patient.
Summary of the invention
Present invention aim to address existing polyurethanes foam dressings easily to breed bacterium, cannot be used for a long time, and easily with
Granulation glues the technical issues of connection, provides a kind of function and service dressing and its preparation side with medicament slow release and from antibacterial effect
Method.
It is as follows that the present invention solves the technical solution that above-mentioned technical problem is taken.
With medicament slow release and from the function and service dressing of antibacterial effect, by successively compact arranged wound connects from the inside to the outside
Contact layer, foam absorber layer and exterior cover sheets composition；
The wound-contacting layer is the composite material of slow releasing pharmaceutical and degradable poly lactic acid, and the mass concentration of slow releasing pharmaceutical is
0.5%~10%, wound-contacting layer with a thickness of 10 μm~150 μm, it is 5 that equally distributed diameter is contained on wound-contacting layer surface
μm~50 μm of penetrating micropore, the hole density of penetrating micropore is 50/cm2~2000/cm2；
The foam absorber layer is aqueous polyurethane foamed material, expansion density 300kg/m3~800kg/m3, foam suction
Receive layer with a thickness of 1mm~100mm, the diameter of open abscess is 5 μm~500 μm；
The aqueous polyurethane foamed material by the base polyurethane prepolymer for use as of 100 parts by weight, the water of 10~30 parts by weight, 2~
The chain extender of 10 parts by weight, the pore-creating agent of 5~10 parts by weight, the foam stabiliser of 2~10 parts by weight, 2~10 parts by weight it is anti-
Microbial inoculum and the catalyst of 0.1~0.5 parts by weight composition；
The exterior cover sheets are the thermoplastic polyurethane of surface compact, with a thickness of 10 μm~150 μm.
Preferably, the slow releasing pharmaceutical is analgestic, in anesthetic, anti-inflammatory drug, coagulant, antipyretic, vitamin
It is one or more.
Preferably, the degradable poly lactic acid is l-lactic acid One of or it is a variety of.
Preferably, the base polyurethane prepolymer for use as is prepared by the following:
By 100~130 DEG C of vacuum dehydrations of polyether polyol, after being cooled to 60~80 DEG C, it is added equipped with diisocyanate
In reaction unit, under inert atmosphere, after 60~80 DEG C of 1~3h of reaction, vacuum defoamation while being cooled to 30~40 DEG C is gathered
Urethane performed polymer；
The polyether polyol is a kind of polypropylene oxide of proportion and the copolymer or more of ethylene oxide copolyether glycol
The mixture of the copolymer of the polypropylene oxide (PO) and ethylene oxide (EO) copolyether glycol of kind of proportion, in copolymer, epoxy
The mass ratio of the material of propane and ethylene oxide is 3:1,1:1,1:3；
The diisocyanate is toluene di-isocyanate(TDI) (TDI) or methyl diphenylene diisocyanate (MDI)；
The mass ratio of the polyether polyol and diisocyanate is 100:(35~400).
Preferably, the antibacterial agent be one of water soluble chitosan, carboxymethyl chitosan, hydroxypropyl chitosan or
It is a variety of.
Preferably, the chain extender is ethylene glycol, 1,4-butanediol, 1,6- hexylene glycol, trimethylolpropane, new penta 2
One of alcohol, pentaerythrite are a variety of；
The foam stabiliser is
One of or it is a variety of；
The catalyst isOne of or it is a variety of.
Preferably, the pore-creating agent is one of Y-1900, K757, LK-303, K2800 or a variety of.
Preferably, the thermoplastic polyurethane is One of or it is a variety of.
The above-mentioned preparation method with medicament slow release and the function and service dressing from antibacterial effect, steps are as follows:
Step 1: preparing wound-contacting layer using submergence phase precipitation transformation method；
Step 2: after thermoplastic polyurethane is completely dissolved deaeration with volatile organic solvent, coated machine even application
It in release paper, is heated by drying tunnel, after organic solvent volatilization drying, release paper is stripped, exterior cover sheets are obtained；
Step 3: by step 1 prepare wound-contacting layer be placed in mold, by the base polyurethane prepolymer for use as of 100 parts by weight,
The water of 10~30 parts by weight, the chain extender of 2~10 parts by weight, the pore-creating agent of 4~10 parts by weight, the foam of 2~10 parts by weight are steady
Determine agent, the antibacterial agent of 2~12 parts by weight and 0.1~0.5 parts by weight catalyst be mixed evenly after, be cast in wound
On contact layer, then in casting layer surface the exterior cover sheets of one layer of step 2 preparation are covered with, curing molding obtains sandwich structure
Compound；
Step 4: taken out after sandwich structure compound is placed in 80~100 DEG C of baking ovens curing 16~for 24 hours, it is natural
It is cooled to room temperature, obtains that there is medicament slow release and the function and service dressing from antibacterial effect.
Preferably, the process of the step 1 are as follows: by the particles of polylactic acid of 100 parts by weight, 10~30 parts by weight it is poly-
Ethylene glycol, 2~12 parts by weight slow releasing pharmaceutical be gradually added in the container containing N-Methyl pyrrolidone, be mixed
Fully dissolved is made into the homogeneous solution that solid content is 20%~60%, after deaeration, coated machine even application in release paper, then
The release paper of mixture layer will be coated with after impregnating 5~30min in ethanol solution, be put into 70~100 DEG C of baking ovens dry it is molten
Agent strips release paper after taking out, obtains wound-contacting layer.
Compared with prior art, the medicine have the advantages that
1, function and service dressing of the invention carries drug slow release function, and has the effect of antibacterial for a long time and sterilization,
It can reduce the frequency that changing dressing for patient uncovers dressing, reduce the injury probability again to wound, during increasing Rehabilitation
Comfortable Experience Degree；
2, the wound-contacting layer of function and service dressing of the invention has used degradable poly lactic acid as skin repair layer, leads to
It crosses polylactic acid and festers in difference and secrete the healing that the degradation rate of the difference in liquid measure carrys out control area skin growth, it is final to rise
To the effect for reducing wound scar；
3, the microfiltration membranes that the wound-contacting layer of function and service dressing of the invention is prepared by immersion precipitation phase inversion process, table
Face aperture size is small, and size distribution is relatively uniform, effectively granulation tissue can be prevented to grow into the abscess of absorbed layer, effectively
Solve the problems, such as dressing and wound adhesion；
4, the foam absorber layer of function and service dressing of the invention has open abscess unit, in saturated absorption juice
Afterwards, still mechanical strength with higher can ensure wound without breakage residual, absorbed inside liquid not reverse osmosis, inside and outside level
Do not have breach；
5, the reasons such as function and service dressing of the invention is particularly suitable for device wound, burn, bacterium infection are festered cause
Skin injury Wound healing and bone regeneration.
Detailed description of the invention
Fig. 1 is the structural schematic diagram with medicament slow release and the function and service dressing from antibacterial effect of the invention；
In figure, 1, wound-contacting layer, 2, foam absorber layer, 3, exterior cover sheets.
Specific embodiment
In order to further appreciate that the present invention, the preferred embodiments of the invention are retouched With reference to embodiment
It states, but it is to be understood that these descriptions are only to further illustrate the features and advantages of the present invention rather than to the invention patent
It is required that limitation.
With medicament slow release and from the function and service dressing of antibacterial effect, by successively compact arranged wound connects from the inside to the outside
Contact layer 1, foam absorber layer 2 and exterior cover sheets 3 form.
Wherein, wound-contacting layer 1 is the composite material of slow releasing pharmaceutical and degradable poly lactic acid, with a thickness of 10 μm~150 μm,
The mass concentration of slow releasing pharmaceutical is 0.5%~10%, and it is 5~50 μm penetrating that the surface of wound-contacting layer 1, which is uniformly distributed diameter,
Micropore, and size distribution is relatively uniform, the hole density of penetrating micropore is 50/cm2~2000/cm2, convenient point of penetrating micropore
Bleeding quickly penetrates into foam absorber layer, effectively granulation tissue can be prevented to grow into the abscess of foam absorber layer, effectively
Solves the problems, such as dressing and wound adhesion；The secretion liquid measure that wound festers affects the degradation rate of polylactic acid, passes through drug
The Healing Rate of release and Degradation Control different zones skin growth finally plays the effect for reducing wound scar.Preferably,
Poly-lactic acid material is l-lactic acid One of or a variety of mixing in any proportion, slow releasing pharmaceutical be analgestic, anesthetic,
One of anti-inflammatory drug, coagulant, antipyretic, vitamin or a variety of mixing in any proportion.
Foam absorber layer 2 is aqueous polyurethane foamed material, with a thickness of 1mm~100mm, expansion density 300kg/m3~
800kg/m3, the open abscess unit that foam absorber layer 2 is 5 μm~500 μm containing diameter, the diameter of open abscess is 5 μ
M~500 μm；After 2 saturated absorption juice of foam absorber layer, still mechanical strength with higher, can ensure wound
Without breakage residual, reverse osmosis, inside and outside level there are not breach to absorbed inside liquid.
Aqueous polyurethane foamed material is by the base polyurethane prepolymer for use as of 100 parts by weight, the water of 10~30 parts by weight, 2~10 weights
Measure the chain extender of part, the pore-creating agent of 4~10 parts by weight, the foam stabiliser of 2~10 parts by weight, 2~12 parts by weight antibacterial agent
It is formed with the catalyst of 0.1~0.5 parts by weight；
Wherein, base polyurethane prepolymer for use as can be commercially available or be prepared by the following: by polyether polyol 100~130
DEG C vacuum dehydration after being cooled to 60~80 DEG C, is added in the reaction unit equipped with diisocyanate, under inert atmosphere, 60~80
DEG C reaction 1~3h after, vacuum defoamation while being cooled to 30~40 DEG C obtains base polyurethane prepolymer for use as；Polyether polyol is one kind
The polypropylene oxide and ethylene oxide of the polypropylene oxide of proportion and the copolymer of ethylene oxide copolyether glycol or a variety of proportions
The mixture of the copolymer of copolyether glycol, in copolymer, the mass ratio of the material of propylene oxide and ethylene oxide be 3:1,1:1,
1:3；Diisocyanate is toluene di-isocyanate(TDI) or methyl diphenylene diisocyanate, polyether polyol and diisocyanate
Mass ratio be 100:(35~400)；
Antibacterial agent be one of water soluble chitosan, carboxymethyl chitosan, hydroxypropyl chitosan or it is a variety of press any ratio
The mixing of example, provides sterilizing ability.Chain extender is ethylene glycol, 1,4- butanediol, 1,6-HD, trimethylolpropane, new penta
One of glycol, pentaerythrite or a variety of mixing in any proportion.Pore-creating agent is Y-1900, K757, LK-303, K2800
One of or a variety of mixing in any proportion.Foam stabiliser is One of or a variety of mixing in any proportion.Catalyst is One of or a variety of mixing in any proportion.
Exterior cover sheets 3 are the thermoplastic polyurethane of surface compact, with a thickness of 10 μm~150 μm.Preferably, thermoplastic
Property polyurethane is One of or a variety of mixing in any proportion.
The above-mentioned preparation method with medicament slow release and the function and service dressing from antibacterial effect, steps are as follows:
Step 1: preparing wound-contacting layer 1 using submergence phase precipitation transformation method；
By the particles of polylactic acid of 100 parts by weight, the polyethylene glycol of 10~30 parts by weight, 2~12 parts by weight slow releasing medicinal
Object is gradually added in the container containing N-Methyl pyrrolidone, and mixing is completely dissolved, be made into solid content be 20%~
60% homogeneous solution, after deaeration, coated machine even application is in release paper, then will be coated with the release paper of mixture layer and pass through
After impregnating 5~30min in ethanol solution, it is put into dry out solvent in 70~100 DEG C of baking ovens, release paper is stripped after taking out, obtains thickness
Degree is 10~150 μm, and the equally distributed penetrating micropore that aperture is 5~50 μm is contained on surface, and hole density is 50/cm2~
2000/cm2Wound-contacting layer；
Step 2: after thermoplastic polyurethane is completely dissolved deaeration with volatile organic solvent, coated machine even application
It in release paper, is heated by drying tunnel, after organic solvent volatilization drying, release paper is stripped, exterior cover sheets 3 are obtained；
Wherein, volatile organic solvent can be using acetone, ethyl alcohol etc.；
Step 3: by step 1 prepare wound-contacting layer 1 be placed in mold, by the base polyurethane prepolymer for use as of 100 parts by weight,
The water of 10~30 parts by weight, the chain extender of 2~10 parts by weight, the pore-creating agent of 5~10 parts by weight, the foam of 2~10 parts by weight are steady
Determine agent, the antibacterial agent of 2~10 parts by weight and 0.1~0.5 parts by weight catalyst be mixed evenly after, be cast in wound
On contact layer 1, then in casting layer surface the exterior cover sheets 3 of one layer of step 2 preparation are covered with, curing molding obtains sandwich knot
Structure compound；
The expansion density of foam absorber layer 2 is 300kg/m3~800kg/m3, foam absorber layer with a thickness of 1mm~
100mm, the diameter of open abscess are 5 μm~500 μm；
Step 4: taken out after sandwich structure compound is placed in 80~100 DEG C of baking ovens curing 16~for 24 hours, it is natural
It is cooled to room temperature, obtains that there is medicament slow release and the function and service dressing from antibacterial effect.
The present invention is further illustrated with reference to embodiments.
Embodiment 1
Step 1: submergence phase precipitation transformation method prepares wound-contacting layer
By 800g'sThe blood coagulation of the polyethylene glycol 200 of 80g, the anesthetic of 8g and 8g
Agent is gradually added in the container containing 5LN- methyl pyrrolidone, and mixing is completely dissolved, and after deaeration, coated machine is uniform
80 DEG C of baking ovens are put into after impregnating 10min in ethanol solution coated in release paper, then by the release paper for being coated with mixture layer
Middle dry out solvent strips release paper after taking out, and obtains with a thickness of 40 μm, and surface apertures are 30 μm, and hole density is 600/cm2's
Wound-contacting layer；
Step 2: the preparation of exterior cover sheets
By 700g'sIt is added in the container containing 2L acetone, stirring and dissolving is uniform, deaeration
Afterwards, coated machine even application strips release paper after taking out, obtains thickness in release paper, being put into dry out solvent in 40 DEG C of baking ovens
The exterior cover sheets that degree is 56 μm；
Step 3: the preparation of function and service dressing
It is cooling by the molecular weight of 2500g is 5000, PO/EO is 3:1 copolyether polyalcohol in 120 DEG C of vacuum dehydrations
To after 70 DEG C, it is added in the reaction unit equipped with 450g toluene di-isocyanate(TDI), under inert atmosphere, after 70 DEG C of reaction 2.5h, drop
Vacuum defoamation while temperature is to 40 DEG C, obtains base polyurethane prepolymer for use as；
In the mold that length, width and height are respectively 200mm*200mm*10mm, bottom is put into wound-contacting layer, by the poly- ammonia of 100g
The water of ester performed polymer and 18g, the 1,4- butanediol of 4g, 5g K2800,5gThe water soluble shells of 8g
Glycan and 0.3g'sUniformly after mixing 40 seconds, it is poured on wound-contacting layer, then exterior cover sheets are covered
It covers after top layer, closed die upper cover, 10min, mold is removed, the molding of sandwich structure compound primary solidification, then will
It is put into 90 DEG C of baking ovens and cures 16h, takes out and is cooled to room temperature, and obtains function and service dressing；
2 expansion density of foam absorber layer is 800kg/m3, foam absorber layer with a thickness of 10mm, the diameter of open abscess
It is 10 μm.
Embodiment 2
Step 1: submergence phase precipitation transformation method prepares wound-contacting layer
By 1000g'sThe polyethylene glycol 200 of 100g, the analgestic of 10g and 10g
Anti-inflammatory drug is gradually added in the container containing 5LN- methyl pyrrolidone, and mixing is completely dissolved, after deaeration, coated machine
Even application is put into 80 DEG C after impregnating 10min in ethanol solution in release paper, then by the release paper for being coated with mixture layer
Dry out solvent in baking oven strips release paper after taking out, and obtains with a thickness of 56 μm, and surface apertures are 40 μm, and hole density is 800/
cm2Wound-contacting layer；
Step 2: the preparation of exterior cover sheets
By 1000g'sIt is added in the container containing 2L acetone, stirring and dissolving is uniform, takes off
After bubble, coated machine even application strips release paper after taking out, obtains in release paper, being put into dry out solvent in 40 DEG C of baking ovens
With a thickness of 82 μm of exterior cover sheets；
Step 3: the preparation of function and service dressing
It is cooling by the molecular weight of 2000g is 4000, PO/EO is 1:1 copolyether polyalcohol in 120 DEG C of vacuum dehydrations
To after 70 DEG C, it is added in the reaction unit equipped with 610g toluene di-isocyanate(TDI), under inert atmosphere, after 70 DEG C of reaction 2.5h, drop
Vacuum defoamation while temperature is to 40 DEG C, obtains base polyurethane prepolymer for use as；
In the mold that length, width and height are respectively 200mm*200mm*10mm, bottom is put into wound-contacting layer, by the poly- ammonia of 100g
The water of ester performed polymer and 25g, the ethylene glycol of 3g, 6g K757,6gThe carboxymethyl chitosan of 10g
And 0.2gUniformly after mixing 30 seconds, it is poured on wound-contacting layer, then exterior cover sheets are covered on most upper
After 10min, mold is removed for layer, closed die upper cover, the molding of sandwich structure compound primary solidification, then puts it into 90
16h is cured in DEG C baking oven, takes out and is cooled to room temperature, obtain function and service dressing；
2 expansion density of foam absorber layer is 300kg/m3, foam absorber layer with a thickness of 55mm, the diameter of open abscess
It is 79 μm.
Embodiment 3
Step 1: submergence phase precipitation transformation method prepares wound-contacting layer
By 600g'sThe polyethylene glycol 200 of 60g, the vitamin of 12g and 8g it is antipyretic
Agent is gradually added in the container containing 5LN- methyl pyrrolidone, and mixing is completely dissolved, and after deaeration, coated machine is uniform
80 DEG C of baking ovens are put into after impregnating 10min in ethanol solution coated in release paper, then by the release paper for being coated with mixture layer
Middle dry out solvent strips release paper after taking out, and obtains with a thickness of 22 μm, and surface apertures are 20 μm, and hole density is 400/cm2's
Wound-contacting layer；
Step 2: the preparation of exterior cover sheets
By 500g'sIt being added in the container containing 2L acetone, stirring and dissolving is uniform, after deaeration,
Coated machine even application strips release paper after taking out in release paper, being put into dry out solvent in 40 DEG C of baking ovens, obtain with a thickness of
34 μm of exterior cover sheets；
Step 3: the preparation of function and service dressing
It is cooling by the molecular weight of 1800g is 3000, PO/EO is 3:1 copolyether polyalcohol in 120 DEG C of vacuum dehydrations
To after 70 DEG C, it is added in the reaction unit equipped with 560g toluene di-isocyanate(TDI), under inert atmosphere, after 70 DEG C of reaction 2.5h, drop
Vacuum defoamation while temperature is to 40 DEG C, obtains base polyurethane prepolymer for use as；
In the mold that length, width and height are respectively 200mm*200mm*10mm, bottom is put into wound-contacting layer, by the poly- ammonia of 100g
The water of ester performed polymer and 20g, the 1,6-HD of 5g, 4g Y-1900,4gThe hydroxypropyl of 12g
Chitosan and 0.3g'sUniformly after mixing 35 seconds, it is poured on wound-contacting layer, then by exterior cover sheets
It is covered on top layer, closed die upper cover after 10min, mold is removed, the molding of sandwich structure compound primary solidification, then
It puts it into 90 DEG C of baking ovens and cures 16h, take out and be cooled to room temperature, obtain function and service dressing；
2 expansion density of foam absorber layer is 500kg/m3, foam absorber layer with a thickness of 80mm, the diameter of open abscess
It is 500 μm.
According to same testing standard, the function and service dressing and function admirable in the prior art of Examples 1 to 3 are detected
Dressing, the results are shown in Table 1.Test method uses medical instrument Registering product standard polyurethane foam dressing (YZB/KR-
WON002-2012 the performance test methods in).
The performance of function and service dressing and the existing dressing of 1 Examples 1 to 3 of table
In table 1, infuse a: the experimental method of bactericidal properties is that dressing sample is made to 10mm*10mm*10mm size square, configuration
The concentration of bacterium solution is 108CUF/mL, and 1mL bacterium solution is added drop-wise in dressing, is fully absorbed, every 30min sampling analysis.
Claims (10)
1. having medicament slow release and the function and service dressing from antibacterial effect, which is characterized in that arranged by successively close from the inside to the outside
Wound-contacting layer, foam absorber layer and the exterior cover sheets composition of column；
The wound-contacting layer is the composite material of slow releasing pharmaceutical and degradable poly lactic acid, and the mass concentration of slow releasing pharmaceutical is
0.5%~10%, wound-contacting layer with a thickness of 10 μm~150 μm, it is 5 that equally distributed diameter is contained on wound-contacting layer surface
μm~50 μm of penetrating micropore, the hole density of penetrating micropore is 50/cm2~2000/cm2；
The foam absorber layer is aqueous polyurethane foamed material, expansion density 300kg/m3~800kg/m3, foam absorber layer
With a thickness of 1mm~100mm, the diameter of open abscess is 5 μm~500 μm；
The aqueous polyurethane foamed material is by the base polyurethane prepolymer for use as of 100 parts by weight, the water of 10~30 parts by weight, 2~10 weights
Measure the chain extender of part, the pore-creating agent of 4~10 parts by weight, the foam stabiliser of 2~10 parts by weight, 2~12 parts by weight antibacterial agent
It is formed with the catalyst of 0.1~0.5 parts by weight；
The exterior cover sheets are the thermoplastic polyurethane of surface compact, with a thickness of 10 μm~150 μm.
2. according to claim 1 have medicament slow release and the function and service dressing from antibacterial effect, which is characterized in that institute
Stating slow releasing pharmaceutical is one of analgestic, anesthetic, anti-inflammatory drug, coagulant, antipyretic, vitamin or a variety of.
3. according to claim 1 have medicament slow release and the function and service dressing from antibacterial effect, which is characterized in that institute
Stating degradable poly lactic acid is l-lactic acid One of or it is a variety of.
4. according to claim 1 have medicament slow release and the function and service dressing from antibacterial effect, which is characterized in that institute
Base polyurethane prepolymer for use as is stated to be prepared by the following:
By 100~130 DEG C of vacuum dehydrations of polyether polyol, after being cooled to 60~80 DEG C, the reaction that diisocyanate is housed is added
In device, under inert atmosphere, after 60~80 DEG C of 1~3h of reaction, vacuum defoamation while being cooled to 30~40 DEG C obtains polyurethane
Performed polymer；
The polyether polyol is the copolymer of polypropylene oxide and the ethylene oxide copolyether glycol of a kind of proportion or a variety of matches
The mixture of the copolymer of the polypropylene oxide and ethylene oxide copolyether glycol of ratio, in copolymer, propylene oxide and epoxy second
The mass ratio of the material of alkane is 3:1,1:1,1:3；
The diisocyanate is toluene di-isocyanate(TDI) or methyl diphenylene diisocyanate；
The mass ratio of the polyether polyol and diisocyanate is 100:(35~400).
5. according to claim 1 have medicament slow release and the function and service dressing from antibacterial effect, which is characterized in that institute
Stating antibacterial agent is one of water soluble chitosan, carboxymethyl chitosan, hydroxypropyl chitosan or a variety of.
6. according to claim 1 have medicament slow release and the function and service dressing from antibacterial effect, which is characterized in that institute
Stating chain extender is one of ethylene glycol, 1,4- butanediol, 1,6-HD, trimethylolpropane, neopentyl glycol, pentaerythrite
Or it is a variety of；
The foam stabiliser isIn
It is one or more；
The catalyst isOne of or it is a variety of.
7. according to claim 1 have medicament slow release and the function and service dressing from antibacterial effect, which is characterized in that institute
Stating pore-creating agent is one of Y-1900, K757, LK-303, K2800 or a variety of.
8. according to claim 1 have medicament slow release and the function and service dressing from antibacterial effect, which is characterized in that institute
Stating thermoplastic polyurethane is One of or it is a variety of.
9. the preparation described in claim 1~8 any one with medicament slow release and the function and service dressing from antibacterial effect
Method, which is characterized in that steps are as follows:
Step 1: preparing wound-contacting layer using submergence phase precipitation transformation method；
Step 2: after thermoplastic polyurethane is completely dissolved deaeration with volatile organic solvent, coated machine even application in from
It on type paper, is heated by drying tunnel, after organic solvent volatilization drying, release paper is stripped, exterior cover sheets are obtained；
Step 3: by step 1 prepare wound-contacting layer be placed in mold, by the base polyurethane prepolymer for use as of 100 parts by weight, 10~
The water of 30 parts by weight, the chain extender of 2~10 parts by weight, the pore-creating agent of 5~10 parts by weight, 2~10 parts by weight foam stabiliser,
After the antibacterial agent of 2~10 parts by weight and the catalyst of 0.1~0.5 parts by weight are mixed evenly, it is cast in wound contact
On layer, then in casting layer surface the exterior cover sheets of one layer of step 2 preparation are covered with, it is compound to obtain sandwich structure curing molding
Object；
Step 4: being taken out, natural cooling after sandwich structure compound is placed in 80~100 DEG C of baking ovens curing 16~for 24 hours
To room temperature, obtain that there is medicament slow release and the function and service dressing from antibacterial effect.
10. the preparation method according to claim 9 with medicament slow release and the function and service dressing from antibacterial effect,
It is characterized in that, the process of the step 1 are as follows: by the particles of polylactic acid of 100 parts by weight, the polyethylene glycol of 10~30 parts by weight, 2
The slow releasing pharmaceutical of~12 parts by weight is gradually added in the container containing N-Methyl pyrrolidone, and mixing is completely dissolved, and is matched
The homogeneous solution for being 20%~60% at solid content, after deaeration, coated machine even application is in release paper, then will be coated with mixing
The release paper of nitride layer is put into dry out solvent in 70~100 DEG C of baking ovens, shells after taking out after impregnating 5~30min in ethanol solution
Except release paper, wound-contacting layer is obtained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810583152.7A CN108939128A (en) | 2018-06-05 | 2018-06-05 | With medicament slow release and from the function and service dressing and preparation method thereof of antibacterial effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810583152.7A CN108939128A (en) | 2018-06-05 | 2018-06-05 | With medicament slow release and from the function and service dressing and preparation method thereof of antibacterial effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108939128A true CN108939128A (en) | 2018-12-07 |
Family
ID=64493700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810583152.7A Pending CN108939128A (en) | 2018-06-05 | 2018-06-05 | With medicament slow release and from the function and service dressing and preparation method thereof of antibacterial effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108939128A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109880052A (en) * | 2019-03-20 | 2019-06-14 | 亳州科蔚科技服务有限公司 | A kind of medical bandage coating preparation method of polyurethane resin compound material |
| CN111001029A (en) * | 2019-12-31 | 2020-04-14 | 泰州市榕兴医疗用品股份有限公司 | Antibacterial foam dressing and preparation method thereof |
| CN111686295A (en) * | 2020-06-24 | 2020-09-22 | 重庆理工大学 | Seepage self-adjusting composite dressing and preparation method thereof |
| CN111746007A (en) * | 2020-06-04 | 2020-10-09 | 振德医疗用品股份有限公司 | Preparation method of anti-adhesion medical polyurethane foam |
| CN112076022A (en) * | 2020-09-29 | 2020-12-15 | 苏州永沁泉智能设备有限公司 | Wound dressing paste and preparation method thereof |
| CN112342496A (en) * | 2019-08-06 | 2021-02-09 | 南京理工大学 | Preparation method of double-layer composite film |
| CN112852207A (en) * | 2021-02-23 | 2021-05-28 | 广东施彩新材料科技有限公司 | Polylactic acid PDLLA slow-release antibacterial agent and preparation method and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050035327A1 (en) * | 2003-08-14 | 2005-02-17 | Canada T. Andrew | Topical silver-based antimicrobial composition for wound care devices |
| US20130150763A1 (en) * | 2011-12-07 | 2013-06-13 | Esmaeil Mirzaei | Electro spun nanofibrous wound dressing and a method of synthesizing the same |
| CN104524986A (en) * | 2014-12-08 | 2015-04-22 | 中国科学院宁波材料技术与工程研究所 | Preparation method of hydrophilic antimicrobial film of which surface is coated with dopamine and polyethyleneimine cations |
| CN105056279A (en) * | 2015-08-12 | 2015-11-18 | 杭州承前生物科技有限公司 | Double-layer polyurethane-based collagen-compounded dressing |
| CN105908363A (en) * | 2016-05-12 | 2016-08-31 | 华南农业大学 | Static spraying composite film and preparation method and application thereof |
| CN106267315A (en) * | 2016-08-14 | 2017-01-04 | 张天奇 | A kind of wound repair dressing |
| CN107029273A (en) * | 2017-04-14 | 2017-08-11 | 苏州医甸园医疗科技发展有限公司 | A kind of compound wound repair dressing based on sea-mussel mucin and polylactic acid microsphere and preparation method and application |
-
2018
- 2018-06-05 CN CN201810583152.7A patent/CN108939128A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050035327A1 (en) * | 2003-08-14 | 2005-02-17 | Canada T. Andrew | Topical silver-based antimicrobial composition for wound care devices |
| US20130150763A1 (en) * | 2011-12-07 | 2013-06-13 | Esmaeil Mirzaei | Electro spun nanofibrous wound dressing and a method of synthesizing the same |
| CN104524986A (en) * | 2014-12-08 | 2015-04-22 | 中国科学院宁波材料技术与工程研究所 | Preparation method of hydrophilic antimicrobial film of which surface is coated with dopamine and polyethyleneimine cations |
| CN105056279A (en) * | 2015-08-12 | 2015-11-18 | 杭州承前生物科技有限公司 | Double-layer polyurethane-based collagen-compounded dressing |
| CN105908363A (en) * | 2016-05-12 | 2016-08-31 | 华南农业大学 | Static spraying composite film and preparation method and application thereof |
| CN106267315A (en) * | 2016-08-14 | 2017-01-04 | 张天奇 | A kind of wound repair dressing |
| CN107029273A (en) * | 2017-04-14 | 2017-08-11 | 苏州医甸园医疗科技发展有限公司 | A kind of compound wound repair dressing based on sea-mussel mucin and polylactic acid microsphere and preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| 何领好等: "《功能高分子材料》", 31 August 2016, 华中科技大学出版社 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109880052A (en) * | 2019-03-20 | 2019-06-14 | 亳州科蔚科技服务有限公司 | A kind of medical bandage coating preparation method of polyurethane resin compound material |
| CN112342496A (en) * | 2019-08-06 | 2021-02-09 | 南京理工大学 | Preparation method of double-layer composite film |
| CN112342496B (en) * | 2019-08-06 | 2022-11-25 | 南京理工大学 | Preparation method of double-layer composite film |
| CN111001029A (en) * | 2019-12-31 | 2020-04-14 | 泰州市榕兴医疗用品股份有限公司 | Antibacterial foam dressing and preparation method thereof |
| CN111001029B (en) * | 2019-12-31 | 2022-01-04 | 泰州市榕兴医疗用品股份有限公司 | Antibacterial foam dressing and preparation method thereof |
| CN111746007A (en) * | 2020-06-04 | 2020-10-09 | 振德医疗用品股份有限公司 | Preparation method of anti-adhesion medical polyurethane foam |
| CN111686295A (en) * | 2020-06-24 | 2020-09-22 | 重庆理工大学 | Seepage self-adjusting composite dressing and preparation method thereof |
| CN112076022A (en) * | 2020-09-29 | 2020-12-15 | 苏州永沁泉智能设备有限公司 | Wound dressing paste and preparation method thereof |
| CN112076022B (en) * | 2020-09-29 | 2022-02-22 | 苏州永沁泉智能设备有限公司 | Wound dressing paste and preparation method thereof |
| CN112852207A (en) * | 2021-02-23 | 2021-05-28 | 广东施彩新材料科技有限公司 | Polylactic acid PDLLA slow-release antibacterial agent and preparation method and application thereof |
| CN112852207B (en) * | 2021-02-23 | 2022-04-01 | 广东施彩新材料科技有限公司 | Polylactic acid PDLLA slow-release antibacterial agent and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108939128A (en) | With medicament slow release and from the function and service dressing and preparation method thereof of antibacterial effect | |
| CN103933602B (en) | The preparation method of chitosan-based medicine carrying composite antibacterial superfine fibre film | |
| US5254301A (en) | Process for preparing a sheet of polymer-based foam | |
| EP1833518B1 (en) | Shortened wound healing processes by means of novel fiber non-wovens | |
| US4550126A (en) | Hydrophilic, flexible, open cell polyurethane-poly(N-vinyl lactam) interpolymer foam and dental and biomedical products fabricated therefrom | |
| JP5020639B2 (en) | Medicinal polyurethane foam | |
| Liu et al. | Gamma-poly glutamate/gelatin composite hydrogels crosslinked by proanthocyanidins for wound healing | |
| Shi et al. | A comparative study of two porous sponge scaffolds prepared by collagen derived from porcine skin and fish scales as burn wound dressings in a rabbit model | |
| US20040018227A1 (en) | Multilayered microporous foam dressing and method for manufacturing the same | |
| CN101613512B (en) | Rapid-imbibing foamed material with antibacterial property and preparation method thereof | |
| ES2261306T3 (en) | REASORBABLE COATING MATERIAL PASSES MEDICINE, PROCEDURE FOR PRODUCTION AND PREPARATION FOR MEDICINE. | |
| CN106693031B (en) | Intelligent dressing capable of controlling pH value of wound and preparation method thereof | |
| KR102144897B1 (en) | Medical Dressing Patch with Chitosan Fabric Sponge Structure Using Chitosan and Method for Preparing the Same | |
| KR100780846B1 (en) | The Method for Manufacturing Polyurethane Foam Dressing that comprises a separate layer including drugs | |
| CN107296975A (en) | A kind of antibacterial anti hemorrhagic based composite dressing for medical use and preparation method thereof | |
| CN110975002A (en) | Hemostatic material for war wounds and preparation method and application thereof | |
| US4625720A (en) | Wound dressing material | |
| CN106110369B (en) | A kind of medical composite type hyaluronic acid dressing and preparation method thereof | |
| CN101927028A (en) | Preparation method of chitosan/ acetalized poval medical dressing | |
| CN108187128A (en) | A kind of absorbable hemostasis bone wax and preparation method thereof | |
| CN108530671A (en) | A kind of porous gelfoam and preparation method thereof | |
| CN110433321A (en) | A kind of preparation method of the medical foam dressing with sustained-release antibacterial | |
| CN108042838B (en) | Preparation method of antioxidant nanofiber electrospun membrane medical dressing | |
| CN112587719A (en) | Antibacterial hemostatic membrane and preparation method and application thereof | |
| CN105944138A (en) | Preparation method of biodegradable medical polyurethane and chitosan composite hemostatic sponge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181207 |
|
| WD01 | Invention patent application deemed withdrawn after publication |